Loading provider…
Loading provider…
Hematology & Oncology Physician in Richmond, VA
NPI: 1124277645Primary Practice Location
MEDICAL COLLEGE OF VIRGINIA HOSPITALS
1213 E Clay St, Richmond, VA
Primary Employer
MCV Associated Physicians
vcuhealth.org
HQ Phone
Get M.D., PH.D., Asit's Phone Numberphone_androidMobile
Get M.D., PH.D., Asit's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardVA State Medical License

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 153 | 366 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 48 | 48 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 43 | 55 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 37 | 47 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 32 | 97 |
Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Authors: Gómez Rivas, Juan, Carrion, Diego M, Alvarez-Maestro, Mario, Cathelineau, Xavier, Sanchez-Salas, Rafael, Di Lorenzo, Giuseppe, Di Maio, Massimo, Paul, Asit, Martinez-Piñeiro, Luis, Sartor, Oliver, Saad, Fred, Debruyne, Francis
Journal: Minerva Urol Nefrol
Publication Date: 2019-07-25
Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies.
Authors: El-Mouallem, Nemer, Paul, Asit K
Journal: Fed Pract
Paraneoplastic Glomerulonephropathy Associated With Renal Cell Carcinoma.
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Olaparib, DRUG: Cediranib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, DRUG: Docetaxel, OTHER: Laboratory Biomarker Analysis, DRUG: Berzosertib
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: Canadian Cancer Trials Group
Intervention / Treatment: DRUG: Atezolizumab